Quest Diagnostics Inc (DGX) Expected to Announce Quarterly Sales of $1.91 Billion

Wall Street brokerages expect Quest Diagnostics Inc (NYSE:DGX) to report $1.91 billion in sales for the current fiscal quarter, Zacks reports. Nine analysts have issued estimates for Quest Diagnostics’ earnings, with the highest sales estimate coming in at $1.97 billion and the lowest estimate coming in at $1.88 billion. Quest Diagnostics posted sales of $1.90 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 0.5%. The company is scheduled to issue its next earnings results on Thursday, April 19th.

On average, analysts expect that Quest Diagnostics will report full-year sales of $1.91 billion for the current fiscal year, with estimates ranging from $7.70 billion to $8.05 billion. For the next financial year, analysts anticipate that the firm will report sales of $8.00 billion per share, with estimates ranging from $7.83 billion to $8.25 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Quest Diagnostics.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, February 1st. The medical research company reported $1.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. Quest Diagnostics had a return on equity of 15.41% and a net margin of 10.00%. Quest Diagnostics’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.31 earnings per share.

A number of equities research analysts have recently issued reports on the company. Credit Suisse Group raised Quest Diagnostics from a “neutral” rating to an “outperform” rating and set a $107.00 target price on the stock in a research report on Tuesday, February 13th. Zacks Investment Research raised Quest Diagnostics from a “hold” rating to a “buy” rating and set a $115.00 target price on the stock in a research report on Tuesday, February 6th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $110.00 target price on shares of Quest Diagnostics in a research report on Thursday, February 1st. Goldman Sachs Group assumed coverage on Quest Diagnostics in a research report on Monday, January 29th. They set a “buy” rating and a $117.00 target price on the stock. Finally, Mizuho set a $113.00 target price on Quest Diagnostics and gave the stock a “buy” rating in a research report on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $107.40.

In other Quest Diagnostics news, EVP J. E. Davis sold 63,880 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $98.68, for a total value of $6,303,678.40. Following the transaction, the executive vice president now directly owns 101,423 shares of the company’s stock, valued at approximately $10,008,421.64. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Chairman Stephen H. Rusckowski sold 106,840 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $107.00, for a total value of $11,431,880.00. Following the completion of the transaction, the chairman now directly owns 272,956 shares in the company, valued at $29,206,292. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 192,014 shares of company stock worth $19,950,134. Insiders own 1.75% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Wagner Wealth Management LLC acquired a new position in Quest Diagnostics in the 4th quarter worth about $106,000. Fuller & Thaler Asset Management Inc. acquired a new position in Quest Diagnostics in the 4th quarter worth about $118,000. Cerebellum GP LLC acquired a new position in Quest Diagnostics in the 4th quarter worth about $128,000. Assetmark Inc. increased its position in Quest Diagnostics by 139.5% in the 4th quarter. Assetmark Inc. now owns 1,473 shares of the medical research company’s stock worth $145,000 after purchasing an additional 858 shares during the last quarter. Finally, Icon Wealth Partners LLC acquired a new position in Quest Diagnostics in the 4th quarter worth about $147,000. 88.67% of the stock is currently owned by institutional investors.

Shares of Quest Diagnostics (NYSE:DGX) opened at $100.85 on Friday. The stock has a market capitalization of $13,890.27, a price-to-earnings ratio of 18.34, a PEG ratio of 1.83 and a beta of 0.67. The company has a current ratio of 1.24, a quick ratio of 1.15 and a debt-to-equity ratio of 0.76. Quest Diagnostics has a 52-week low of $90.10 and a 52-week high of $112.96.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 18th. Shareholders of record on Wednesday, April 4th will be given a $0.50 dividend. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.45. This represents a $2.00 annualized dividend and a yield of 1.98%. The ex-dividend date is Tuesday, April 3rd. Quest Diagnostics’s dividend payout ratio is presently 32.73%.

ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/23/quest-diagnostics-inc-dgx-expected-to-announce-quarterly-sales-of-1-91-billion.html.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Get a free copy of the Zacks research report on Quest Diagnostics (DGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply